Class B G-protein-coupled receptors are exciting drug targets, yet the structure of a complete receptor bound to a peptide agonist has remained elusive. Coin et al. present a model of the receptor CRF1R bound to its native ligand based on partial structures and 44 spatial constraints revealed by new crosslinking approaches.
G-protein-coupled receptors (GPCRs) represent the largest class of membrane receptors. They transmit highly diverse signals across the cell membrane and form the most important class of drug targets. Over the last several years, GPCR structural biology has greatly expanded our knowledge on the recognition of agonists and antagonists of class A GPCRs, which form the bulk of this receptor group . In contrast, class B GPCRs have only 15 members, all of which are medically important and are pursued as therapeutic targets. The physiological ligands of class B GPCRs are peptides rather than small molecules, and the receptors differ from class A GPCRs by their large extracellular domains that are the main contributors to peptide affinity and selectivity. Whereas the C terminus of peptide agonists is anchored by the extracellular domain, the N terminus penetrates the transmembrane domain, which is thought to induce conformational changes at the cytoplasmic side, leading to receptor activation (Pal et al., 2012; Parthier et al., 2009) .
Although the crystal structures of the thermostabilized transmembrane domains of two class B receptors have recently been solved (Hollenstein et al., 2013; Siu et al., 2013) , structural information on ligand recognition is limited to isolated class B extracellular domains bound to peptide agonists (Pioszak et al., 2008; Pal et al., 2010) . In this issue of Cell, Coin et al. (2013) report a generalizable procedure to map the interface between the class B receptor corticotrophinreleasing factor receptor type 1 (CRF1R) and one of its ligands, the 40 amino acid peptide urocortin-1 (Ucn1).
CRF1R and the closely related receptor CRF2R comprise a subclass of class B GPCR and play crucial roles in modulating stress responses in the central nervous system, as well as in metabolic regulation. Their peptide ligands include CRF and three urocortin peptides (Unc1, Unc2, and Unc3) (Bale and Vale, 2004) . Several structures related to peptide recognition by the CRF receptors are known, including the CRF1R extracellular domain bound to the C terminus of CRF (Pioszak et al., 2008) and the CRF2R extracellular domain bound to the C-terminal portions of CRF1 and the three urocortin peptides (Pal et al., 2010) . However, it has been unclear how the N terminus of the ligand interacts with the transmembrane domain to initiate signaling.
To gain insight into ligand binding, the authors first map Ucn1-binding sites on CRF1R by expressing 146 receptor mutants that each contain a genetically introduced amino acid derivative (azidophenylalanine [Azi]), which is a UV-activated crosslinker. Collectively, mutated residues nearly covered the complete extracellular half of the transmembrane domain, including the extracellular loops and the linker to the extracellular domain. UV irradiation of cells activates Azi to crosslink nearby residues, and 35 of 140 expressed mutant proteins yield covalent adducts with Ucn1, as detected by immunoblotting with anti-Unc1 antibodies. This indicates that these receptor residues are in close proximity to Ucn1, providing a map of the Ucn1 binding pocket in the CRF1R transmembrane domains. Second, to position the ligand in the pocket, the authors generate a new set of mutants, each one with a genetically introduced phenylalanine analog, p-2 0 -fluoroacetyl-phenylalanine (Ffact), at one of the 23 pocket sites that yield the strongest Azi crosslinking signals. Ffact forms covalent bonds with nearby cysteine residues, which are strategically placed in the peptide ligand. The crosslinking results can therefore identify specific pairs of receptor-peptide ligand residues in close proximity to each other. Cells expressing the mutant proteins were incubated with each of five different Ucn1 peptides that contain a cysteine residue either at position 6, 8, 10, 12, or 14, yielding 115 possible proximity combinations. Nine of those yielded CRF1R-Ucn1 crosslinking adducts that could be identified by immunoblotting, indicating that the eighth, twelfth, and fourteenth residues of the peptide are in proximity to the extracellular side of transmembrane domains 6 and 7. Finally, the authors derive a conformational model based on the structures of the CRF1R extracellular domain/CRF complex, Ucn1, and the CRF1R transmembrane domain that fulfills all constraints of the nine CRF1R-Ucn1 pairs and the 35 residues of the transmembrane domain binding pocket.
Although the model provides a wealth of information, it also has some limitations. It positions only an eight amino acid N-terminal stretch (residues 6-14) of the 40 amino acid peptide and only toward transmembrane domain helices 6 and 7 (Figure 1 ). The latter is surprising, as the five introduced Ucn1 cysteines also face helices 1, 2, 3, and 5, whose residues would be, according to the model, appropriately spaced for crosslinking. Second, the model is based on the X-ray structure of the CRF1R transmembrane domain in the inactive conformation, bound to a small-molecule antagonist (Hollenstein et al., 2013) , whereas CRF1R bound to its agonist Ucn1 would be expected to adopt an active conformation. Yet, the transmembrane helices of the inactive structure and the model are superimposable with the sole exception of a 3 Å inward tilt of the tip of helix 7, which is required to satisfy Ffact-Cys and Azi distance constraints. Overall, the model provides important insight into the relative position of the N terminus of Ucn1 but likely does not present all aspects of the conformation of the CRF1R-Ucn1 complex, including conformational changes at both the extracellular and cytoplasmic sides of the receptor.
The strength of the new approach is that it can be applied in principle to any complex for which an initial structural model exists, that it uses standard lab technologies in combination with the two unnatural amino acids (Azi and Ffact phenylalanine analogs), and that the spatial constraints are determined in live cells with intact, fully posttranslationally modified proteins in their physiological membrane environment. We therefore anticipate that it may find widespread applications. However, it is clear that this approach is a complement to structure determination by X-ray crystallography or nuclear magnetic resonance (NMR) rather than an alternative to these techniques, and we therefore still await the first high-resolution structure of a class B GPCR bound to a physiological peptide agonist. For now, the model revealed by the genetically engineered constraints provides the best alternative. 
